Climb Bio (CLYM)

• Market cap: $618M
• 1 day: 1.02%
• 5 days: 1.3%
• 1 month: -1.89%
• 3 months: 48.84%
• 6 months: 374.35%
• Year to date: 190.93%
• 1 year: 765.87%
• 5 years: -31.38%
• 10 years: -31.38%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Employees: 29